Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
|Articles|May 13, 2022
Daily OTC Pearl: Phazyme
Author(s)Saro Arakelians, PharmD
Phazyme is used to treat symptoms of gas, such as belching, bloating, and pressure in the stomach/gut.
Advertisement
OTC/Lifestyle Pearl of the Day: Phazyme
Indication: Phazyme is used to treat symptoms of gas, such as belching, bloating, and pressure in the stomach/gut.
Insight:
- Simethicone 250 mg.
- Comes in fast gel capsules. Swallow 1 or 2 fast gels as symptoms occur.
- Relieves bloating, pressure, and fullness.
- Store at room temperature.
Source:
Advertisement
Related to this article
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
3
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
4
From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF
5